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retrospective US medicare claim base data analysis have been shown to signiﬁcantly 
decrease mortality risk of a VCF patient when treated with BKP compared to NSM. 
Aim of this study is the evaluation of resource usage and costs for treatment of BKP 
patients in comparison to NSM patients from a social insurance perspective. 
METHODS: In this prospective, non-randomised follow-up-study treatment and costs 
were evaluated in 8 study centers in Germany between 2005 and 2008. Data was 
recorded by questionnaires at baseline and by phone at follow-up. Resource usage 
was valued by DRG for inpatient treatment, EBM fur outpatient treatment and 
Lauer-taxe for medication. RESULTS: The higher initial DRG treatment costs in the 
BKP arm are partially off-set by lower follow-up costs (Follow-up DRG costs: BKP: 
a131.08; NSM: a1149.75; Mann-Whitney-U: p  0.006; Outpatient treatment: BKP: 
a860.57; NSM: a991.65; Mann-Whitney-U: p  0,300; Medication: BKP: a136.56; 
NSM: a338.42; Mann-Whitney-U: p  0.007). Total costs for the BKP patients were 
a 3,874.12 higher than for the NSM patients (Mann-Whitney-U: p  0.000). Compared 
to NSM, BKP treated patients had signiﬁcantly shorter hospital stay for both the initial 
and follow-up hospitalization (9.6 versus 14.7, p  0.000 and in follow-up hospitaliza-
tion 10.7 versus 17.7, p  0.005). CONCLUSIONS: The higher baseline costs of BKP 
versus NSM are partially off-set by reduced follow-up treatment costs. The remaining 
additional costs have to be weighted against shorter hospital stay and improved clinical 
outcomes. Full economic evaluations of BKP versus NSM in the UK, Italy and Spain 
have already demonstrated the cost-effectiveness of BKP versus NSM.
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OBJECTIVES: TNF-A inhibitors are becoming a widely used treatment option for 
rheumatoid arthritis (RA) in the South African private sector. Justiﬁcation for reim-
bursement decisions range from pure list price comparisons to cost of treatment com-
parisons, with limited use of health economics, since South African private health care 
funders have a developing understanding of health economics. The objective of this 
cost of treatment comparison is to estimate the total direct medical costs associated 
with the use of TNF-A inhibitors for the treatment of RA in the South African private 
sector. METHODS: This analysis compares the cost of treatment using the results of 
the DART dose escalation study comparing etanercept, adalimumab and inﬂiximab. 
The expected direct medical costs were estimated over a one year period under two 
scenarios (dose escalation and no dose escalation) and included the costs of TNF-A 
inhibitors, administration, consultation and dispensing. The scenario excluding dose 
escalation was based on minimum label dose and the dose escalation scenario was 
based on 12 months of actual dosing of each TNF-A inhibitor from the DART data. 
Cost values were estimated from the perspective of the South African private health 
care funder. RESULTS: Total direct medical costs associated with the use of etaner-
cept, adalimumab and inﬂiximab are respectively R118,235, R118,357 and R121,481 
per person based on the DART dose escalation study. The cost associated with adali-
mumab is 5% lower compared with etanercept and inﬂiximab when the effect of dose 
escalation is not taken into account. The total cost of treatment for the total popula-
tion of private sector RA patients using TNF-A inhibitors is 77 million ZAR (a6.9 
million). CONCLUSIONS: The direct medical costs associated with the use of TNF-A 
inhibitors for the treatment of RA patients in South Africa are similar despite the dif-
ferences in list prices of these agents.
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OBJECTIVES: To establish the total direct medical cost of patients in second-line TNF 
a therapy from the French heath care system perspective. METHODS: A multicentre 
observational study was conducted, recruiting patients treated since at least four 
months by a second TNF a therapy. The sample represented was assessed through the 
comparison of the regional allocation of inclusions to the regional allocation of TNF 
a prescriptions issued from a national panel. Inpatient and outpatient consumptions 
were collected retrospectively, for the preceding four months. Respect of clinical 
practice recommendations was assessed through the analysis of administration fre-
quencies and posologies. RESULTS: Fifty-nine hospital centres participated in the 
study, including 277 patients. The sample could be considered as representative as 
the correlation between the regional activity in terms of TNF a prescriptions and the 
number of included patients per region was high (r  0.88). The resulting total annual 
direct medical cost equalled a16,000 per patient. Respectively 43, 132, and 102 
patients were included in the INF, ETA and ADA groups. Two patients treated 
by INF received more than the expected number of administrations, whereas 8 others 
had a higher dosage than that recommended. Respectively 11.4% and 24.5% of 
patients treated by ETA and ADA also received more administrations than expected 
during the 4 months of treatment. CONCLUSIONS: This representative study 
stated that hospitalisation costs represented 92% of the total direct medical costs of 
patients treated by a second-line TNF a therapy, reaching a16,000 per patient and 
per year. In the absence of a speciﬁc market authorisation in the indication, TNF a 
therapies are prescribed, but the clinical practice recommendations are not always 
respected.
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OBJECTIVES: to examine the cost-beneﬁt of management strategies for reducing road 
trafﬁc injuries. METHODS: The study was a cross-sectional analysis of secondary 
data retrieved from the Injury Surveillance (IS) in the ﬁscal year 2004 to 2006. The 
sample consisted of all trafﬁc accidental patients who received hospital emergency 
services. The two dependent variables used were direct medical cost and death, mul-
tiple linear regression models and binary logistic regression models were constructed. 
The outputs of management strategies: non-use of crash helmets and drunk driving 
were explained by using Monte Carlo technique. RESULTS: The study covered 12,651 
patients. For the regression analysis, statistically signiﬁcant predictors were composed 
of sex, age, drunk driving, non-use of crash helmets, accidental timing, victim and 
severity (adjusted R2  0.60). For the binary logistic regression analysis, odd-ratio of 
the causes of death of non-use of safety equipments (helmet and seatbelt) and drunk 
driving were 3.56 (CI 2.62–4.85) and 1.24 (CI 1.01–1.53) respectively. The direct 
medical cost arrived at from using the regression model when using law enforcement 
with 50 percent succession of both strategies was THB20,983,413.59. Compare with 
the current situation, it was THB26,709,449.76 (21.44% save). In the same way, the 
net beneﬁt gain from these enforcement was THB512,894,977.48. (58.44% save). 
Nevertheless, changing each assumption of the successful management strategies from 
10% to 50%, the sensitivity analysis shows the range of saving from 24.67% to 
58.44% and the beneﬁt to cost ratio was 10.81. CONCLUSIONS: These ﬁndings 
show the scenario to reduce trafﬁc injury, the law enforcement strategies for using 
safety equipment and reduce the number drunk driving is a useful management tool 
to reduce cost of illness nearly three-quarters of the damages from road trafﬁc 
injuries.
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OBJECTIVES: Biologic agents are commonly used sequentially to treat moderate to 
severe rheumatoid arthritis (RA). In absence of clinical trials comparing biologic 
strategies, simulation models are useful to inform decisions. The objective is to 
assess, using the NHS perspective, the cost-effectiveness of biologic strategies in 
patients with an insufﬁcient response (IR) to at least 1 anti-TNF agent. METHODS: 
Simulation models were developed to assess four strategies of different biologic agents 
over 2 years. Assuming an IR to the 1st anti-TNF agent, Sequence 1 included etaner-
cept-abatacept-adalimumab and Sequence 2 etanercept-rituximab-adalimumab. 
Assuming an IR to 2 anti-TNF agents, Sequence 3 included etanercept-adalimumab-
abatacept and Sequence 4 etanercept-adalimumab-inﬂiximab. Effectiveness data was 
derived from published evidence based on achieving a low disease activity state 
(LDAS). Switch occurred at each 6 months in case of an IR to the previous agent. 
UK direct medical costs and biologic drug costs were used. Extensive probabilistic 
sensitivity analyses were performed. RESULTS: There were 6-month medical costs 
(excluding biologic drug costs) were estimated at £1047 (Standard Deviation [SD] 
332) for managing patients in LDAS and at £2650 (SD 963) for moderate-to-high 
disease activity. Over 2 years, Sequence 1 appeared more efﬁcacious (92 days in LDAS) 
versus Sequence 2 (82 days in LDAS,) with cost-effectiveness ratios of £281/day in 
LDAS vs. £289/day in LDAS, respectively. Sequence 3 appeared more efﬁcacious (43 
days in LDAS or) vs. Sequence 4 (32 days in LDAS), with cost-effectiveness ratios of 
£603/day in LDAS vs. £809/day in LDAS, respectively. CONCLUSIONS: Medical 
costs associated with moderate-to-high disease activity are estimated to be 2.5 times 
higher than for LDAS, suggesting that efﬁcacious treatment strategies contribute to 
reducing use of health care services. The results of this simulation model suggest that, 
for achieving LDAS, sequences including abatacept after an IR to at least 1 anti-TNF 
agent appear more cost-effective than similar sequences including rtx or cycled anti-
TNF agents.
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OBJECTIVES: Several studies have demonstrated that compliant and long-term use 
of bisphosphonates is necessary to realize full beneﬁts of treatment. In particular, a 
progressive relation between compliance (medication possession ratio above 80%) and 
fracture risk reduction has been found (Siris, Mayo Clin Proc 2006;81:1013–22 and 
Penning, Osteoporos Int 2008;19:511–17). Taking into account patient compliance, 
we compared the effectiveness and costs of zoledronic acid (ZOL) versus weekly 
alendronate & risedronate and monthly ibandronate therapies over 3 years in the 
prevention of postmenopausal osteoporotic fractures from the NHS perspective of 
Turkey, using Number Needed to Treat (NNT) approach. METHODS: NNT values 
